Global Dilated Cardiomyopathy Drugs and Companies Pipeline Review H2 2016

The report provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/619253-dilated-cardiomyopathy-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy

- The report reviews pipeline therapeutics for Dilated Cardiomyopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Dilated Cardiomyopathy therapeutics and enlists all their major and minor projects

- The report assesses Dilated Cardiomyopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Dilated Cardiomyopathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Dilated Cardiomyopathy Overview 6

Therapeutics Development 7

Pipeline Products for Dilated Cardiomyopathy - Overview 7

Dilated Cardiomyopathy - Therapeutics under Development by Companies 8

Dilated Cardiomyopathy - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Unknown Stage Products 11

Dilated Cardiomyopathy - Products under Development by Companies 12

Dilated Cardiomyopathy - Companies Involved in Therapeutics Development 13

Array BioPharma Inc. 13

Capricor Therapeutics, Inc. 14

Hemostemix Ltd 15

Kasiak Research Private Limited 16

Sanofi 17

Vericel Corporation 18

Dilated Cardiomyopathy - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

ACP-01 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

ARRY-797 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Access Report @ https://www.wiseguyreports.com/reports/619253-dilated-cardiomyopathy-pipeline-review-h2-2016                                             

Contact Info:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)                                                   

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts